Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL DYSLEXIA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL DYSLEXIA TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL DYSLEXIA TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 EPIDEMIOLOGY
7 INDUSTRY INSIGHTS
8 PREMIUM INSIGHTS
9 REGULATORY SCENARIO
10 PIPELINE ANALYSIS
10.1 OVERVIEW
10.2 LATE STAGE PRODUCTS (PHASE III) CANDIDATES
10.3 MID-STAGE PRODUCTS (PHASE II) CANDIDATES
10.4 EARLY-STAGE PRODUCT (PHASE I) CANDIDATES
10.5 PRE-CLINICAL (DISCOVERY STAGE) CANDIDATES
11 GLOBAL DYSLEXIA TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 DOUBLE DEFICIT DYSLEXIA
11.3 VISUAL DYSLEXIA
11.4 PHONOLOGICAL DYSLEXIA
11.5 RAPID NAMING DYSLEXIA
11.6 SURFACE DYSLEXIA
11.7 OTHERS
12 GLOBAL DYSLEXIA TREATMENT MARKET, BY TREATMENT
12.1 OVERVIEW
12.2 THERAPY
12.2.1 OCCUPATIONAL THERAPY
12.2.2 SPEECH THERAPY
12.2.3 COGNITIVE BEHAVIOURAL THERAPY
12.2.4 VISUAL & AUDITORY THERAPIES
12.2.5 OTHERS
12.3 DRUGS
12.3.1 ANTIHISTAMINE
12.3.1.1. CYCLIZINE
12.3.1.2. MECLIZINE
12.3.1.3. DIMENHYDRINATE
12.3.1.4. OTHERS
12.3.2 CENTRAL NERVOUS STIMULANT
12.3.2.1. METHYLPHENIDATE
12.3.2.2. DEXTROAMPHETAMINE
12.3.2.3. DOPAMINE
12.3.2.4. OTHERS
12.3.3 ANTI-MYOCLONIC
12.3.4 PIRACETAM
12.3.5 ATOMOXETINE
12.3.6 OTHERS
12.4 OTHERS
13 GLOBAL DYSLEXIA TREATMENT MARKET, BY DRUG TYPE
13.1 OVERVIEW
13.2 BRANDED
13.2.1 RITALIN
13.2.2 DEXEDRINE
13.2.3 ADDERALL
13.2.4 STRATTERA
13.2.5 PIRAMAX
13.2.6 OTHERS
13.3 GENERIC
14 GLOBAL DYSLEXIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 PARENTERAL
14.3.1 INTRAVENOUS
14.3.2 SUBCUTANEOUS
14.3.3 OTHERS
14.4 OTHERS
15 GLOBAL DYSLEXIA TREATMENT MARKET, BY AGE GROUP
15.1 OVERVIEW
15.2 CHILDREN
15.3 ADULTS
15.3.1 MALE
15.3.2 FEMALE
16 GLOBAL DYSLEXIA TREATMENT MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 CLINICS
16.4 SPECIALTY CENTRES
16.5 PSYCHIATRIC INSTITUTIONS
16.6 REHABILITATION CENTERS
16.7 HOMECARE
16.8 OTHERS
17 GLOBAL DYSLEXIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 HOSPITAL PHARMACIES
17.3 RETAIL PHARMACIES
17.4 ONLINE PHARMACIES
17.5 OTHERS
18 GLOBAL DYSLEXIA TREATMENT MARKET, SWOT AND DBMR ANALYSIS
19 GLOBAL DYSLEXIA TREATMENT MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
19.3 COMPANY SHARE ANALYSIS: EUROPE
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.5 MERGERS & ACQUISITIONS
19.6 NEW PRODUCT DEVELOPMENT & APPROVALS
19.7 EXPANSIONS
19.8 REGULATORY CHANGES
19.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20 GLOBAL DYSLEXIA TREATMENT MARKET, BY REGION
GLOBAL DYSLEXIA TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
20.1 NORTH AMERICA
20.1.1 U.S.
20.1.2 CANADA
20.1.3 MEXICO
20.2 EUROPE
20.2.1 GERMANY
20.2.2 U.K.
20.2.3 ITALY
20.2.4 FRANCE
20.2.5 SPAIN
20.2.6 RUSSIA
20.2.7 SWITZERLAND
20.2.8 TURKEY
20.2.9 BELGIUM
20.2.10 NETHERLANDS
20.2.11 DENMARK
20.2.12 SWEDEN
20.2.13 POLAND
20.2.14 NORWAY
20.2.15 FINLAND
20.2.16 REST OF EUROPE
20.3 ASIA-PACIFIC
20.3.1 JAPAN
20.3.2 CHINA
20.3.3 SOUTH KOREA
20.3.4 INDIA
20.3.5 SINGAPORE
20.3.6 THAILAND
20.3.7 INDONESIA
20.3.8 MALAYSIA
20.3.9 PHILIPPINES
20.3.10 AUSTRALIA
20.3.11 NEW ZEALAND
20.3.12 VIETNAM
20.3.13 TAIWAN
20.3.14 REST OF ASIA-PACIFIC
20.4 SOUTH AMERICA
20.4.1 BRAZIL
20.4.2 ARGENTINA
20.4.3 REST OF SOUTH AMERICA
20.5 MIDDLE EAST AND AFRICA
20.5.1 SOUTH AFRICA
20.5.2 EGYPT
20.5.3 BAHRAIN
20.5.4 UNITED ARAB EMIRATES
20.5.5 KUWAIT
20.5.6 OMAN
20.5.7 QATAR
20.5.8 SAUDI ARABIA
20.5.9 REST OF MEA
21 GLOBAL DYSLEXIA TREATMENT MARKET, COMPANY PROFILE
21.1 NOVARTIS AG
21.1.1 COMPANY OVERVIEW
21.1.2 REVENUE ANALYSIS
21.1.3 GEOGRAPHIC PRESENCE
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 TRIS PHARMA, INC.
21.2.1 COMPANY OVERVIEW
21.2.2 REVENUE ANALYSIS
21.2.3 GEOGRAPHIC PRESENCE
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
21.3.1 COMPANY OVERVIEW
21.3.2 REVENUE ANALYSIS
21.3.3 GEOGRAPHIC PRESENCE
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 SUN PHARMACEUTICAL INDUSTRIES LTD
21.4.1 COMPANY OVERVIEW
21.4.2 REVENUE ANALYSIS
21.4.3 GEOGRAPHIC PRESENCE
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.5.1 COMPANY OVERVIEW
21.5.2 REVENUE ANALYSIS
21.5.3 GEOGRAPHIC PRESENCE
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 MALLINCKRODT
21.6.1 COMPANY OVERVIEW
21.6.2 REVENUE ANALYSIS
21.6.3 GEOGRAPHIC PRESENCE
21.6.4 PRODUCT PORTFOLIO
21.6.5 RECENT DEVELOPMENTS
21.7 MAYNE PHARMA
21.7.1 COMPANY OVERVIEW
21.7.2 REVENUE ANALYSIS
21.7.3 GEOGRAPHIC PRESENCE
21.7.4 PRODUCT PORTFOLIO
21.7.5 RECENT DEVELOPMENTS
21.8 NOVEL LABORATORIES, INC.
21.8.1 COMPANY OVERVIEW
21.8.2 REVENUE ANALYSIS
21.8.3 GEOGRAPHIC PRESENCE
21.8.4 PRODUCT PORTFOLIO
21.8.5 RECENT DEVELOPMENTS
21.9 ENDO PHARMACEUTICALS, INC.
21.9.1 COMPANY OVERVIEW
21.9.2 REVENUE ANALYSIS
21.9.3 GEOGRAPHIC PRESENCE
21.9.4 PRODUCT PORTFOLIO
21.9.5 RECENT DEVELOPMENTS
21.1 AMNEAL PHARMACEUTICALS LLC
21.10.1 COMPANY OVERVIEW
21.10.2 REVENUE ANALYSIS
21.10.3 GEOGRAPHIC PRESENCE
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENTS
21.11 ALVOGEN
21.11.1 COMPANY OVERVIEW
21.11.2 REVENUE ANALYSIS
21.11.3 GEOGRAPHIC PRESENCE
21.11.4 PRODUCT PORTFOLIO
21.11.5 RECENT DEVELOPMENTS
21.12 BIONPHARMA
21.12.1 COMPANY OVERVIEW
21.12.2 REVENUE ANALYSIS
21.12.3 GEOGRAPHIC PRESENCE
21.12.4 PRODUCT PORTFOLIO
21.12.5 RECENT DEVELOPMENTS
21.13 ANI PHARMACEUTICALS, INC.
21.13.1 COMPANY OVERVIEW
21.13.2 REVENUE ANALYSIS
21.13.3 GEOGRAPHIC PRESENCE
21.13.4 PRODUCT PORTFOLIO
21.13.5 RECENT DEVELOPMENTS
21.14 ASCENT PHARMACEUTICALS, INC.
21.14.1 COMPANY OVERVIEW
21.14.2 REVENUE ANALYSIS
21.14.3 GEOGRAPHIC PRESENCE
21.14.4 PRODUCT PORTFOLIO
21.14.5 RECENT DEVELOPMENTS
21.15 BRECKENRIDGE PHARMACEUTICAL, INC.
21.15.1 COMPANY OVERVIEW
21.15.2 REVENUE ANALYSIS
21.15.3 GEOGRAPHIC PRESENCE
21.15.4 PRODUCT PORTFOLIO
21.15.5 RECENT DEVELOPMENTS
21.16 IRONSHORE PHARMACEUTICALS, INC.
21.16.1 COMPANY OVERVIEW
21.16.2 REVENUE ANALYSIS
21.16.3 GEOGRAPHIC PRESENCE
21.16.4 PRODUCT PORTFOLIO
21.16.5 RECENT DEVELOPMENTS
21.17 ALKEM LABS
21.17.1 COMPANY OVERVIEW
21.17.2 REVENUE ANALYSIS
21.17.3 GEOGRAPHIC PRESENCE
21.17.4 PRODUCT PORTFOLIO
21.17.5 RECENT DEVELOPMENTS
21.18 FRESENIUS KABI AG
21.18.1 COMPANY OVERVIEW
21.18.2 REVENUE ANALYSIS
21.18.3 GEOGRAPHIC PRESENCE
21.18.4 PRODUCT PORTFOLIO
21.18.5 RECENT DEVELOPMENTS
21.19 GLAXOSMITHKLINE PLC
21.19.1 COMPANY OVERVIEW
21.19.2 REVENUE ANALYSIS
21.19.3 GEOGRAPHIC PRESENCE
21.19.4 PRODUCT PORTFOLIO
21.19.5 RECENT DEVELOPMENTS
21.2 LUPIN PHARMACEUTICALS
21.20.1 COMPANY OVERVIEW
21.20.2 REVENUE ANALYSIS
21.20.3 GEOGRAPHIC PRESENCE
21.20.4 PRODUCT PORTFOLIO
21.20.5 RECENT DEVELOPMENTS
21.21 ELI LILLY AND COMPANY
21.21.1 COMPANY OVERVIEW
21.21.2 REVENUE ANALYSIS
21.21.3 GEOGRAPHIC PRESENCE
21.21.4 PRODUCT PORTFOLIO
21.21.5 RECENT DEVELOPMENTS
21.22 ASTRAZENECA
21.22.1 COMPANY OVERVIEW
21.22.2 REVENUE ANALYSIS
21.22.3 GEOGRAPHIC PRESENCE
21.22.4 PRODUCT PORTFOLIO
21.22.5 RECENT DEVELOPMENTS
21.23 PFIZER INC
21.23.1 COMPANY OVERVIEW
21.23.2 REVENUE ANALYSIS
21.23.3 GEOGRAPHIC PRESENCE
21.23.4 PRODUCT PORTFOLIO
21.23.5 RECENT DEVELOPMENTS
21.24 THE HIMMEL GROUP
21.24.1 COMPANY OVERVIEW
21.24.2 REVENUE ANALYSIS
21.24.3 GEOGRAPHIC PRESENCE
21.24.4 PRODUCT PORTFOLIO
21.24.5 RECENT DEVELOPMENTS
21.25 RPG LIFE SCIENCES LTD.
21.25.1 COMPANY OVERVIEW
21.25.2 REVENUE ANALYSIS
21.25.3 GEOGRAPHIC PRESENCE
21.25.4 PRODUCT PORTFOLIO
21.25.5 RECENT DEVELOPMENTS
21.26 WALLACE PHARMACEUTICAL LTD.
21.26.1 COMPANY OVERVIEW
21.26.2 REVENUE ANALYSIS
21.26.3 GEOGRAPHIC PRESENCE
21.26.4 PRODUCT PORTFOLIO
21.26.5 RECENT DEVELOPMENTS
21.27 APOTEX CORPORATION
21.27.1 COMPANY OVERVIEW
21.27.2 REVENUE ANALYSIS
21.27.3 GEOGRAPHIC PRESENCE
21.27.4 PRODUCT PORTFOLIO
21.27.5 RECENT DEVELOPMENTS
22 RELATED REPORTS
23 CONCLUSION
24 QUESTIONNAIRE
25 ABOUT DATA BRIDGE MARKET RESEARCH
